MJMadhan Kumar Soutallu Janakiram

Madhan Kumar Soutallu Janakiram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Madhan Kumar Soutallu Janakiram has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunotherapeutic Advances in Alzheimer’s Disease: The Convergence of Vaccinology and Nanoscience

    by Hanish Singh Jayasingh Chellammal, Ashok Kumar Janakiraman, Dhani Ramachandran, Ronald Darwin Chellappan, Mohamed Saleem Thattakudian Sheikuduman, Madhan Kumar Soutallu Janakiram, Hemanth Kumar Boyina, Mohamed Shabi Mohamed Abdul Kader, Senthil Kumar Kannan, Raju Sugavasi

    Amyloid-beta plaques and neurofibrillary tangles promote neuronal dysfunction and cognitive loss, the hallmarks of Alzheimer's disease (AD), a serious global health concern. Current medications offer only symptomatic alleviation, emphasizing the critical need for disease-- modifying therapy. This study was performed using MeSH term search by using keywords, like “Alzheimer’s Disease”, “AD”, “Vaccines”, “Nanoformulations”, “Amyloid-Beta (Aβ) Vaccines”, “lecanemab”, “Tau protein Vaccines”, “AADvac1”, “Clinical trials”. The development of vaccines and methods based on nanotechnology is the primary focal point of this review, which explores immunotherapeutic approaches. Active and passive immunization are used in the development of AD vaccines to target tau and amyloid-beta pathology. While passive immunization involves the direct delivery of pre-formed antibodies, active immunization aims to stimulate the patient's own immune system to produce antibodies in response to the antigen. The necessity for effective drug delivery across the blood-brain barrier (BBB), safety issues, and inconsistent efficacy are some of the difficulties facing vaccine delivery strategies. Nanotechnology can overcome the drawbacks of traditional treatments by providing novel approaches for gene therapy, RNA-based interventions, and targeted medication administration. Immunization approaches offer multiple benefits, including regulated and targeted antigen release, as well as stabilizing the vaccine antigens. Therapeutic drugs can be delivered across the BBB, and genes linked to AD can be modulated by nanoparticles and liposomes that resemble exosomes. Current developments, including the incorporation of short Aβ epitopes, liposomal formulations, conformational mimotopes, and virus-- like particles (VLPs), have markedly enhanced vaccine tolerability. Effective AD treatments depend on combination medications, individualized approaches, and ongoing research into crossing the BBB and improving the safety and effectiveness of vaccines.

  • Open Access

    ADVANCES IN POLYPHENOL-BASED OCULAR DRUG DELIVERY: MECHANISTIC INSIGHTS, FORMULATION INNOVATIONS, AND TRANSLATIONAL PERSPECTIVES

    by Ashok Kumar Janakiraman, Mouneeshwaran Moorthy, Madhan Kumar Soutallu Janakiram, Saminathan Kayarohanam, Cheng Wan Hee, Mohamed Saleem Ts, Ravi Sheshala, Hanish Singh Jayasingh Chellammal

    Polyphenols, a structurally diverse class of plant-derived phytoconstituents, possess potent antioxidant, anti-inflammatory, and vasoprotective properties that make them promising therapeutic candidates for ocular disorders driven by oxidative stress, chronic inflammation, and overall health. Despite this potential, their clinical translation remains restricted due to the inherent limitations of conventional ocular delivery systems, such as low ocular bioavailability, rapid precorneal elimination, poor corneal permeability, and inadequate targeting of posterior ocular tissues. To address these challenges, recent research has focused on advanced formulation approaches designed to enhance polyphenol retention, penetration, and sustained release within ocular tissues. These include nanoemulsions, polymeric micelles lipid and polymer-based nanocarriers, in situ gelling systems, mucoadhesive and stimuli-responsive platforms, and advanced drug delivery platforms for the posterior and anterior ocular segments. Mechanistically, these systems exploit physicochemical and biological strategies such as enhancing mucoadhesion, modulating paracellular transport, and leveraging endocytic uptake to improve drug disposition and therapeutic performance. The review critically examines these innovative formulation platforms, delineates their pharmacokinetic and pharmacodynamic outcomes, and discusses safety, manufacturing challenges, and regulatory considerations that presently influence their clinical progression. Overall, it highlights emerging formulation technologies most likely to facilitate the successful clinical translation of polyphenol-based ocular therapies.

  • Open Access

    An Axillary Arch Muscle Variant with Potential Neurovascular Implications

    by Alfonzo E Munoz, Mathew Mendoza, Madhan Kumar Soutallu Janakiram, Chakravarthy M Sadacharan, S M Niazur Rahman

    The axillary arch (AA), also known as Langer’s axillary arch, is the most common muscular variation encountered in the axilla. It typically arises from the latissimus dorsi and traverses the axillary fossa, often crossing anterior to the neurovascular structures before inserting into the pectoralis major or surrounding fascia. Although frequently asymptomatic, this variant may cause neurovascular compression or complicate surgical procedures involving the axilla. During routine cadaveric dissection, an axillary arch muscle was identified in a 97-year-old male donor. The muscular slip originated from the medial border of the latissimus dorsi and inserted into the trilaminar tendon of the pectoralis major, passing anterior to the axillary artery and median nerve. No additional muscular variations were observed. This report highlights the anatomical features and clinical relevance of the axillary arch and emphasizes the importance of recognizing this variation to avoid diagnostic confusion and surgical complications.

  • Open Access

    Histological and Immunohistochemical Study of the Beta Cells In Streptozotocin Induced Diabetic Rats Treated with Cynodon Dactylon Aqueous Extract

    by Madhan Kumar Soutallu Janakiram, Raju Sugavasi, Radhakrishna Shetty Kommanda, Parthiban Govindarajoo, Muthuvel Mani

    Background: Diabetes mellitus is a chronic metabolic disorder that affects human body in terms of physical, psychological and social health. Traditional medicines have been widely used in treatment of diabetes and its complications. After administrating the aqueous extract of Cynodon dactylon in streptozotocin induced diabetic rats, we evaluated the histological and immunohistochemical effects of the β – cells in the pancreatic islets. Objectives: The objective of the present study is to investigate the antidiabetic effect of Cynodon dactylon aqueous extract in β – cells of islets, against streptozotocin induced diabetic rats. Materials and Methods: In this study adult male albino rats were used. Aqueous extract of Cynodon dactylon (500 mg/kg.bw/day) administered orally for 45 days. At the end of experimental period, animals were sacrificed, pancreas was isolated and processed for histological and immunohistochemical analysis. Results: The pancreas of Cynodon dactylon aqueous extract treated diabetic rats showed improved islet morphology; and the pancreatic islets of the Cynodon dactylon aqueous extract treated diabetic rats showed consistent elevation in the insulin levels from the β – cells. Therefore, the antidiabetic activity of Cynodon dactylon aqueous extract might be due to the compounds present in the Cynodon dactylon aqueous extract which stimulate the insulin secretion and protect the intact functional β – cells from streptozotocin induced destruction. Conclusion: Cynodon dactylon aqueous extract increased the insulin secreting β – cells in the pancreatic islets and protecting the intact β – cells from oxidative damage. KEYWORDS: Cynodon dactylon, streptozotocin, Pancreatic islets, oxidative stress.